DaVita (DVA) and Molina Healthcare (MOH) on Torvanta's measures: DVA grades higher on 3 of the 4 factor families and MOH on 0.
| DVA | MOH | |
|---|---|---|
| Value grade | A | D- |
| Growth grade | B | D- |
| Profitability grade | C+ | D- |
| Momentum grade | D+ | D+ |
| Market value | $11.2B | $11.5B |
| P/E (trailing) | 14.4x | 2200.2x |
| Forward P/E (Torvanta model estimate) | Subscribers | Subscribers |
| Revenue, last 12 months | $14.0B | $44.5B |
| Revenue growth (y/y) | +6% | +3% |
| Operating margin | 15.2% | 0.5% |
| Return on invested capital | 17.9% | 5.4% |
| Free-cash-flow yield | 14.4% | 2.3% |
| Total return, 1 year | +36.6% | +11.4% |
| Total return, 3 years | +125.7% | -36.9% |
Full DVA analysis · Full MOH analysis
DaVita (DVA) and Molina Healthcare (MOH) on Torvanta's measures: DVA grades higher on 3 of the 4 factor families and MOH on 0. Which fits an investor depends on their goals; this is research, not a recommendation. Subscribers see where the model ranks each and its expected return.
On trailing earnings DVA trades at 14.4x and MOH at 2200.2x; their value grades are A and D- against their sectors.
Subscribers get a rating, a fair value estimate, a 12-month target and a risk read for every S&P 500 company, Torvanta's earnings estimates, and three model portfolios (Active, Adaptive and Patient) with every trade sized and explained. A free account includes 3 full Stock Analyst reports a month.
See plans Or get the free weekly newsletterTorvanta is research only - not investment advice and not a recommendation to buy or sell any security. Grades describe a company's reported data against its sector; they are not the model's view, change as data changes and can be wrong. Financial figures come from the company's SEC filings; returns include reinvested dividends. Past performance does not predict future results.
All stock ratings · Stock lists · AI stock research · Model portfolio · Research · Disclaimer
Data powered by Tiingo.com